PSILOCINMED.COM

WELCOME TO PSILOCINMED.COM

PSILOCINMED.COM is singular metabolite English: Psilocin Med—clinics, compounding consults, and research desks that already say “psilocin med” when they mean the active tryptamine pathway in medical conversations, not plural catalog Meds inventory.

Best-fit buyers: psychedelic clinics; research publishers; investor IR microsites; defensive holders. Exact-fit launch: a Psilocin Med explainer with mechanism tiles, trial FAQ, and clinician CTA—buyer owns all DEA/FDA clearances.

Compass Pathways reported that COMP360 (synthetic psilocybin) met its Phase 3 COMP005 primary endpoint: a −3.6 MADRS difference vs placebo at week 6 (p<0.001), with FDA Breakthrough Therapy designation for treatment-resistant depression.^[1] COMP005 Part A dosed 258 participants across 32 U.S. sites—the pivotal scale buyers already cite when they underwrite medical-psychedelic brandables.^[2] That Phase 3 spine frames why exact Psilocin Med inventory matters—not an invented category TAM.

Why Choose PSILOCINMED.COM

• 🧪 Psilocin Med lockup: Singular metabolite medical English already spoken.
• 📉 Phase 3 signal: COMP005 −3.6 MADRS at week 6 (Compass).^[1]
• 🏥 Pivotal scale: 258 participants / 32 U.S. sites (COMP005 Part A).^[2]
• 🔍 Vs PsilocinMeds: Singular Med door ≠ plural Meds catalog.
• 📋 Compliance-first: Buyer owns DEA Schedule I / FDA pathway work.
• ✨ Clinic clarity: Sounds like a research-landing mechanism page.

BUY NOW - $30,238

Buy Now — PSILOCINMED.COM. Own the Psilocin Med hostname.

Purchase PSILOCINMED.COM today through our trusted partners:

• GoDaddy
• Xela Domains
• Afternic

WHAT DOES ARNOLD ISA THINK?

"PsilocinMed.com is singular medical inventory—Psilocin Med, not plural Meds catalog."

Arnold Isa, Broker
Contact Arnold Isa via Email

Related Domains

FAQs

Who buys PsilocinMed.com?

Clinics, research publishers, IR microsites, and defensive holders.

What figures are cited?

Compass COMP005: −3.6 MADRS week 6; 258 participants / 32 U.S. sites.

Is this FDA-approved medicine?

No—descriptive brandable; COMP360 remains investigational; buyer owns all clearances.

Vs PsilocinMeds.com?

Singular Med vs plural Meds—unique siblings.

Contact Us

Feel free to reach out to explore the potentials of PSILOCINMED.COM for your business. 📬

📧 Email: info@xeladomains.com
📞 Phone: (858) 429-9352

Social Networks

Follow us on Instagram and LinkedIn to stay updated on the latest trends and opportunities in psychedelic medicine with PSILOCINMED.COM.

Instagram | LinkedIn

REFERENCES

1. Compass Pathways — COMP005 Phase 3: COMP360 25 mg vs placebo −3.6 MADRS at week 6 (p<0.001); FDA Breakthrough Therapy for TRD
2. Compass Pathways — COMP005 Part A: 258 participants dosed across 32 U.S. sites (synthesized psilocybin TRD pivotal)